Prognostic value of left ventricular hypertrophy assessed with 15O-water positron emission tomography
European Heart Journal - Imaging Methods and Practice · 02.07.2026 · 4 (3)
DOI: 10.1093/ehjimp/qyag121 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Heart Journal - Imaging Methods and Practice, online erschienen am 03.07.2026. Verfasst von Jonathan Sigfridsson und 6 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging and Medical Physics, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Heart-Lung Foundation.
Abstract (Originalsprache)
Aims
Left ventricular (LV) hypertrophy is associated with adverse cardiac outcomes. LV mass index (LVMi) and interventricular septal wall thickness (WT) can be derived from 15O-water positron emission tomography (PET), but their prognostic value is unknown. We aimed to assess the prognostic value and test–retest repeatability of PET-derived LV hypertrophy metrics in patients evaluated for suspected coronary artery disease (CAD). Methods and results We retrospectively included 783 consecutive patients referred for rest-stress PET. LVMi and WT were determined on non-ECG-gated resting 15O-water PET scans. Subjects were stratified by previous heart failure (HF) diagnosis and patients with known hypertrophic/infiltrative cardiomyopathy were excluded. The primary outcome was major adverse cardiac events (MACE: cardiovascular death or acute HF). The prognostic value of LV hypertrophy measurements was evaluated using Cox hazard ratios (HR [95% confidence interval]). Test–retest repeatability was evaluated in prospective data from 21 patients with repeated PET scans. Patients with known HF but no hypertrophic/infiltrative cardiomyopathy (18%) had significantly higher LVMi (P < 0.0001) and WT (P = 0.0015) compared to subjects without HF (82%). Among patients without HF, 30 experienced MACE during a median 3.8 year follow up. Both LVMi (HR 1.04 [1.02–1.06] per g/m2, P < 0.0001) and WT (HR 1.36 [1.10–1.68] per mm, P = 0.0045) independently predicted MACE after adjustment for sex, age and myocardial flow reserve. Test–retest repeatability was high, with no significant bias.
Conclusion
PET LV hypertrophy metrics can be robustly quantified from routine 15O-water PET and provide prognostic information beyond myocardial perfusion.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Molecular Imaging and Medical Physics, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
- Uppsala/Gävleborg County, Centre for Research and Development, Gävle, Sweden.
ORCID-Profile: Jonathan Sigfridsson, Tanja Kero, Jens Sörensen
Förderung
- Swedish Heart-Lung Foundation
Zitieren
APA
Sigfridsson, J., Svanström, P., Kero, T., Harms, H. J., Nordström, J., Lubberink, M., & Sörensen, J. (2026). Prognostic value of left ventricular hypertrophy assessed with 15O-water positron emission tomography. European Heart Journal - Imaging Methods and Practice, 4(3). https://doi.org/10.1093/ehjimp/qyag121
Vancouver
Sigfridsson J, Svanström P, Kero T, Harms HJ, Nordström J, Lubberink M, et al. Prognostic value of left ventricular hypertrophy assessed with 15O-water positron emission tomography. European Heart Journal - Imaging Methods and Practice. 2026;4(3). doi:10.1093/ehjimp/qyag121
BibTeX
@article{Sigfridsson2026,
author = {Sigfridsson, Jonathan and Svanström, Patrik and Kero, Tanja and Harms, Hendrik J and Nordström, Jonny and Lubberink, Mark and Sörensen, Jens},
title = {Prognostic value of left ventricular hypertrophy assessed with 15O-water positron emission tomography},
journal = {European Heart Journal - Imaging Methods and Practice},
year = {2026},
volume = {4},
number = {3},
doi = {10.1093/ehjimp/qyag121}
}
EUVIMED